Cell and gene therapy enters 2026 as a field of potentially curative medicine with a stubbornly small customer base. The science has delivered one-time genetic interventions for diseases that once meant a lifetime of transfusions, progressive disability, or early death. The business model, in many cases, has not: these are expensive, operationally complex products that…